Five-Day Treatment with B. licheniformis Along with Classical Vancomycin Treatment Was Effective in Preserving Gut Microbiota in Patients with Clostridioides difficile Infection

被引：0
作者：
Gweon, Tae-Geun [1 ,2 ]
Kang, Sang-Bum [1 ,3 ]
Na, Soo-Young [1 ,4 ]
Oh, Dong Jun [5 ]
Kim, Sang Wook [6 ]
Seo, Geom Seog [7 ]
Cho, Joo Young [8 ]
机构：
[1] Catholic Univ Korea, Coll Med, Dept Internal Med, Seoul 02812, South Korea
[2] Catholic Univ Korea, Bucheon St Marys Hosp, Coll Med, Dept Internal Med, Bucheon 14662, South Korea
[3] Catholic Univ Korea, Daejeon St Marys Hosp, Coll Med, Dept Internal Med, Daejeon 34943, South Korea
[4] Catholic Univ Korea, Incheon St Marys Hosp, Coll Med, Dept Internal Med, Incheon 21431, South Korea
[5] Dongguk Univ, Ilsan Hosp, Dept Internal Med, Goyang 10326, South Korea
[6] Jeonbuk Natl Univ Hosp, Dept Internal Med, Jeonju 54907, South Korea
[7] Wonkwang Univ Hosp, Digest Dis Res Inst, Dept Internal Med, Iksan 54538, South Korea
[8] Cha Med Ctr Gangnam, Dept Internal Med, Seoul 06135, South Korea
来源：
NUTRIENTS | 2025年 / 17卷 / 04期
关键词：
<italic>Clostridioides difficile</italic> infection; <italic>Bacillus licheniformis</italic>; probiotic; microbiota; IRRITABLE-BOWEL-SYNDROME; TRANSPLANTATION; GUIDELINES;
D O I：
10.3390/nu17040641
中图分类号：
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号：
100403 ;
摘要：
Background/Objectives: Clostridioides difficile infection (CDI) is an important nosocomial diarrheal disease. The benefits of the probiotic Bacillus licheniformis (B. licheniformis) in the preservation of intestinal microbiota have not been studied in patients with CDI to date. Therefore, we aimed to investigate the efficacy of B. licheniformis in preserving the intestinal microbiota in patients with CDI. Methods: A multicenter, randomized, placebo-controlled trial was carried out at six academic centers in Korea. Individuals diagnosed with mild to moderate CDI were included in this trial. CDI was treated with vancomycin 125 mg four times daily for two weeks. Along with vancomycin, B. licheniformis was administered for five days in this study, while a placebo was given to the placebo group. Microbiome analysis was performed before and five days after administering vancomycin and B. licheniformis or placebo, using 16S rRNA amplicon sequencing. Alpha and beta diversity was compared between the two groups. Results: A total of 35 participants were finally included in this study, with 16 in the study group and 19 in the placebo group. The alpha diversity was similar in both groups before CDI treatment. After five days of the administration of vancomycin and B. licheniformis or placebo, alpha diversity did not decrease in the study group (Chao1 index, p = 0.665; observed features, p = 0.692). In contrast, alpha diversity decreased in the placebo group (Chao1 index, p = 0.011; observed features, p = 0.011). Beta diversity did not differ between the two groups. Conclusions: The addition of B. licheniformis to vancomycin was effective in preserving gut microbiota in patients with CDI.
引用
收藏
页数：12
相关论文
共 39 条
  • [1] Ananthakrishnan A.N., Clostridium difficile infection: Epidemiology, risk factors and management, Nat. Rev. Gastroenterol. Hepatol, 8, pp. 17-26, (2011)
  • [2] Winter S.E., Baumler A.J., Gut dysbiosis: Ecological causes and causative effects on human disease, Proc. Natl. Acad. Sci. USA, 120, (2023)
  • [3] Lessa F.C., Mu Y., Bamberg W.M., Beldavs Z.G., Dumyati G.K., Dunn J.R., Farley M.M., Holzbauer S.M., Meek J.I., Phipps E.C., Et al., Burden of Clostridium difficile infection in the United States, N. Engl. J. Med, 372, pp. 825-834, (2015)
  • [4] Baek J., Choi I., Cho Y., Kim J., Lee Y., Kim M., Kim K., Cho Y.-S., Clinical characteristics and outcomes of Clostridioides difficile infection in the intensive care unit: A KASID multi-centre study, J. Hosp. Infect, 139, pp. 106-112, (2023)
  • [5] Guh A.Y., Mu Y., Winston L.G., Johnston H., Olson D., Farley M.M., Wilson L.E., Holzbauer S.M., Phipps E.C., Dumyati G.K., Et al., Trends in U.S. Burden of Clostridioides difficile Infection and Outcomes, N. Engl. J. Med, 382, pp. 1320-1330, (2020)
  • [6] Feuerstadt P., Theriault N., Tillotson G., The burden of CDI in the United States: A multifactorial challenge, BMC Infect. Dis, 23, (2023)
  • [7] Collins D.A., Hawkey P.M., Riley T.V., Epidemiology of Clostridium difficile infection in Asia, Antimicrob. Resist. Infect. Control, 2, (2013)
  • [8] Borren N.Z., Ghadermarzi S., Hutfless S., Ananthakrishnan A.N., The emergence of Clostridium difficile infection in Asia: A systematic review and meta-analysis of incidence and impact, PLoS ONE, 12, (2017)
  • [9] Kim J., Myung R., Kim B., Kim J., Kim T., Lee M.S., Kim U.J., Park D.W., Kim Y.S., Lee C.S., Et al., Incidence of Clostridioides difficile Infections in Republic of Korea: A Prospective Study with Active Surveillance vs. National Data From Health Insurance Review & Assessment Service, J. Korean Med. Sci, 39, (2024)
  • [10] Wadhwa A., Al Nahhas M.F., Dierkhising R.A., Patel R., Kashyap P., Pardi D.S., Khanna S., Grover M., High risk of post-infectious irritable bowel syndrome in patients with Clostridium difficile infection, Aliment. Pharmacol. Ther, 44, pp. 576-582, (2016)
1234